An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: Effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity

Journal of Medicinal Chemistry

Volumn 50, Issue 11, 2007, Pages 2622-2639

  Dawson, Marcia I ^a   Xia, Zebin ^a   Liu, Gang ^a   Fontana, Joseph A ^b   Farhana, Lulu ^b   Patel, Bhamik B ^b   Arumugarajah, Sankari ^b   Bhuiyan, Mohammad ^b   Zhang, Xiao Kun ^a   Han, Young Hoon ^a   Stallcup, William B ^a   Fukushi, Jun Ichi ^a,g   Mustelin, Tomas ^a   Tautz, Lutz ^a   Su, Ying ^a   Harris, Danni L ^c   Waleh, Nahid ^f   Hobbs, Peter D ^f   Jong, Ling ^f   Chao, Wan Ru ^f   Schiff, Leonard J ^e   Sani, Brahma P ^d   more..

^a BURNHAM INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOLECULAR RESEARCH INSTITUTE   (United States)

^d SOUTHERN RESEARCH INSTITUTE   (United States)

^e IIT RESEARCH INSTITUTE   (United States)

^f SRI INTERNATIONAL   (United States)

^g KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 4 NITROPHENYL TRIFLUOROMETHANESULFONATE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 CHLORO 4 HYDROXYBENZONITRILE; 3 CHLOROBENZYLIDENETHIAZOLIDINE 2,4 DIONE DERIVATIVE; 3 CHLOROPHENYLTETRAZOLE; 3' (1 ADAMANTYL) 4' BENZYLOXY 2 CHLORO 4 NITROBIPHENYL; 4 [3' (1 ADAMANTYL) 4' BENZYLOXYPHENYL] 3 CHLOROCINNAMALDEHYDE; 4 [3' (1 ADAMANTYL) 4' HYDROXYPHENYL] 3 CHLOROCINNAMIC ACID; 4 BENZYLOXY 3 CHLOROBENZONITRILE; 5 [3 (3' (1 ADAMANTYL) 2 CHLORO 4' HYDROXY 4 BIPHENYL) 2 PROPENYLIDENE] 2,4 THIAZOLIDINEDIONE; ADAMANTANE DERIVATIVE; BORONIC ACID DERIVATIVE; CARBOXYLIC ACID; CELL NUCLEUS RECEPTOR; DIETHYL 2 [3' (1 ADAMANTYL) 4' BENZYLOXY 2 CHLORO 4 BIPHENYL]ETHENYLPHOSPHONIC ACID; HETERODIMER; HYDROXAMIC ACID; NITRILE; PHOSPHONIC ACID DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; RETINOID DERIVATIVE; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG INHIBITION; ELECTRICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ADAMANTANE; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CINNAMATES; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; HUMANS; MICROCIRCULATION; PROTEIN-TYROSINE-PHOSPHATASE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETINOIDS; STEREOISOMERISM;

EID: 34250173035     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0613323     Document Type: Article

References (78)

1. Bernard, B. A.; Bernardon, J. M.; Delescluse, C.; Martin, B.; Lenoir, M. C.; Maignan, J.; Charpentier, B.; Pilgrim, W. R.; Reichert, U.; Shroot, B. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem. Biophys. Res. Commun. 1992, 186, 977-983.
2. Charpentier, B.; Bernardon, J. M.; Eustache, J.; Millois, C.; Martin, B.; Michel, S.; Shroot, B. Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J. Med. Chem. 1995, 38, 4993-5006.
3. 1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995, 11, 493-504.
4. WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res. 1996, 56, 5055-5062.
5. Zhang, Y.; Dawson, M. I.; Mohammad, R.; Rishi, A. K.; Farhana, L.; Feng, K. C.; Leid, M.; Peterson, V.; Zhang, X. K.; Edelstein, M.; Eilander, D.; Biggar, S.; Wall, N.; Reichert, U.; Fontana, J. A. Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood 2002, 100, 2917-2925.
6. Dawson, M. I.; Harris, D. L.; Liu, G.; Hobbs, P. D.; Lange, C. W.; Jong, L.; Bruey-Sedano, N.; James, S. Y.; Zhang, X. K.; Peterson, V. J.; Leid, M.; Farhana, L.; Rishi, A. K.; Fontana, J. A. Antagonist analogue of 6-[3′-(1-adamantyl)-4′-hydroxyphenyl]-2-naphthalene-carboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest. J. Med. Chem. 2004, 47, 3518-3536.
7. Farhana, L.; Dawson, M. I.; Fontana, J. A. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-κB activation. Cancer Res. 2005, 65, 4909-4917.
8. Zhang, Y.; Dawson, M. I.; Ning, Y.; Polin, L.; Parchment, R. E.; Corbett, T.; Mohamed, A. N.; Feng, K. C.; Farhana, L.; Rishi, A. K.; Hogge, D.; Leid, M.; Peterson, V. J.; Zhang, X. K.; Mohammad, R.; Lu, J. S.; Willman, C.; VanBuren, E.; Biggar, S.; Edelstein, M.; Eilender, D.; Fontana, J. A. Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. Blood 2003, 102, 3743-3752.
9. Han, Y. H.; Cao, X.; Lin, B.; Lin, F.; Kolluri, S. K.; Stebbins, J.; Reed, J. C.; Dawson, M. I.; Zhang, X.-K. Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt. Oncogene 2006, 25, 2974-2986.
10. Widschwendter, M.; Berger, J.; Muller, H. M.; Zeimet, A. G.; Marth, C. Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J. Mammary Gland Biol. Neoplasia 2001, 6, 193-201.
11. Lotan, R. Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res. 1996, 16, 2415-2419.
12. Lynch, C. J.; Milner, J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: A basis for p53 haploinsufficiency. Oncogene 2006, 25, 3463-3470.
13. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C p53 mutations in human cancers. Science 1991, 253, 49-53.
14. Farhana, L.; Dawson, M. I.; Leid, M.; Wang, L.; Moore, D. D.; Liu, G.; Xia, Z.; Fontana, J. A. Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor. Cancer Res. 2007, 67, 318-325.
15. Borgius, L. J.; Steffensen, K. R.; Gustafsson, J. A.; Treuter, E. Glucocorticoid signaling is perturbed by the atypical orphan receptor and corepressor SHP. J. Biol. Chem. 2002, 277, 49761-49766.
16. Brendel, C.; Schoonjans, K.; Botrugno, O. A.; Treuter, E.; Auwerx, J. The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol. Endocrinol. 2002, 16, 2065-2076.
17. Gobinet, J.; Carascossa, S.; Cavailles, V.; Vignon, F.; Nicolas, J. C.; Jalaguier, S. SHP represses transcriptional activity via recruitment of histone deacetylases. Biochemistry 2005, 44, 6312-6320.
18. Kassam, A.; Capone, J. P.; Rachubinski, R. A. The short heterodimer partner receptor differentially modulates peroxisome proliferator-activated receptor alpha-mediated transcription from the peroxisome proliferator-response elements of the genes encoding the peroxisomal beta-oxidation enzymes acyl-CoA oxidase and hydratase-dehydrogenase. Mol. Cell. Endocrinol. 2001, 176, 49-56.
19. Klinge, C. M.; Jernigan, S. C.; Risinger, K. E.; Lee, J. E.; Tyulmenkov, V. V.; Falkner, K. C.; Prough, R. A. Short heterodimer partner (SHP) orphan nuclear receptor inhibits the transcriptional activity of aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT). Arch. Biochem. Biophys. 2001, 390, 64-70.
20. Seol, W.; Chung, M.; Moore, D. D. Novel receptor interaction and repression domains in the orphan receptor SHP. Mol. Cell. Biol. 1997, 17, 7126-7131.
21. Yeo, M. G.; Yoo, Y. G.; Choi, H. S.; Pak, Y. K.; Lee, M. O. Negative cross-talk between Nur77 and small heterodimer partner and its role in apoptotic cell death of hepatoma cells. Mol. Endocrinol. 2005, 19, 950-63.
22. Dhanabal, M.; Jeffers, M.; Larochelle, W. J. Anti-angiogenic therapy as a cancer treatment paradigm. Curr. Med. Chem. Anticancer Agents 2005, 5, 115-130.
23. Blagosklonny, M. V. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 2004, 23, 2967-2975.
24. Fenaux, P.; De Botton, S. Retinoic acid syndrome. Recognition, prevention and management. Drug Saf 1998, 18, 273-279.
25. Cheer, S. M.; Foster, R. H. Alitretinoin. Am. J. Clin. Dermatol. 2000, 1, 307-314; discussion 315-316.
26. Dawson, M. I.; Chan, R. L.; Derdzinski, K.; Hobbs, P. D.; Chao, W. R.; Schiff, L. J. Synthesis and pharmacological activity of 6-[(E)-2-(2,6,6- trimethyl-1-cyclohexen-1-yl)ethenl-yl]- and 6-(1,2,3,4-tetrahydro-1,1,4,4- tetramethyl-6-naphthyl)-2-naphthalenecarboxylic acids. J. Med. Chem. 1983, 26, 1653-1656.
27. Newton, D. L.; Henderson, W. R.; Sporn, M. B. Structure-activity relationships of retinoids in hamster tracheal organ culture. Cancer Res. 1980, 40, 3413-3425.
28. Strickland, S.; Breitman, T. R.; Frickel, F.; Nurrenbach, A.; Hadicke, E.; Sporn, M. B. Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL60 promyelocytic leukemia cells. Cancer Res. 1983, 43, 5268-5272.
29. Verma, A. K.; Shapas, B. G.; Rice, H. M.; Boutwell, R. K. Correlation of the inhibition by retinoids of tumor promoter-induced mouse epidermal ornithine decarboxylase activity and of skin tumor promotion. Cancer Res. 1979, 39, 419-425.
30. Sporn, M. B.; Roberts, A. B. Biological methods for analysis and assay of retinoids: Relationships between structure and activity. In The Retinoids; Sporn, M. B.; Roberts, A. B.; Goodman, D. S., Eds.; Academic Press, Inc.: Orlando, FL, 1984; Chapter 5, Vol. 1, pp 236-279.
31. Schiff, L. J.; Okamura, W. H.; Dawson, M. I.; Hobbs, P. D. Structure-biological activity relationships of new synthetic retinoids on epithelial differentiation of cultured hamster trachea. In Chemistry and Biology of Synthetic Retinoids; Dawson, M. I.; Okamura, W. H., Eds.; CRC Press: Boca Raton, FL, 1990; pp 307-363.
32. Dawson, M. I.; Chao, W.-R.; Hobbs, P. D.; Delair, T. The inhibitory effects of retinoids on the induction of ornithine decarboxylase and the promotion of tumors in mouse epidermis. In Chemistry and Biology of Synthetic Retinoids; Dawson, M. I.; Okamura, W. H., Eds.; CRC Press: Boca Raton, FL, 1990; pp 385-466.
33. Cincinelli, R.; Dallavalle, S.; Nannei, R.; Carella, S.; De Zani, D.; Merlini, L.; Penco, S.; Garattini, E.; Giannini, G.; Pisano, C.; Vesci, L.; Carminati, P.; Zuco, V.; Zanchi, C.; Zunino, F. Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity. J. Med. Chem. 2005, 48, 4931-4946.
34. Parrella, E.; Gianni, M.; Fratelli, M.; Barzago, M. M.; Raska, I. J.; Diomede, L.; Kurosaki, M.; Pisano, C.; Carminati, P.; Merlini, L.; Dallavalle, S.; Tavecchio, M.; Rochette-Egly, C.; Terao, M.; Garattini, E. Antitumor activity of the retinoid related molecules, ST 1926 and CD437, in F9 teratocarcinoma: Role of retinoic acid receptor γ and retinoid-independent pathways. Mol. Pharmacol. 2006, 70, 909-924.
35. Dawson, M. I.; Hobbs, P. D.; Peterson, V. J.; Leid, M.; Lange, C. W.; Feng, K. C.; Chen, G.; Gu, J.; Li, H.; Kolluri, S. K.; Zhang, X.; Zhang, Y.; Fontana, J. A. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res. 2001, 61, 4723-4730.
36. Robertson, K. A.; Emami, B.; Collins, S. J. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992, 80, 1885-1889.
37. Tashima, T.; Kagechika, H.; Tsuji, M.; Fukasawa, H.; Kawachi, E.; Hashimoto, Y.; Shudo, K. Polyenylidene thiazolidinedione derivatives with retinoidal activities. Chem. Pharm. Bull. (Tokyo) 1997, 45, 1805-1813.
38. Ebisawa, M.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Itai, A.; Shudo, K.; Kagechika, H. Novel thiazolidinedione derivatives with retinoid synergistic activity. Biol. Pharm. Bull. 1998, 21, 547-549.
39. Yang, D. Y. 4-Hydroxyphenylpyruvate dioxygenase as a drug discovery target. Drug News Perspect. 2003, 16, 493-496.
40. Renaud, J. P.; Rochel, N.; Ruff, M.; Vivat, V.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of the RAR-α ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378, 681-689.
41. Klaholz, B. P.; Mitschler, A.; Belema, M.; Zusi, C.; Moras, D. Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARα. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6322-6327.
42. Fontana, J. A.; Dawson, M. I.; Leid, M.; Rishi, A. K.; Zhang, Y.; Hsu, C. A.; Lu, J. S.; Peterson, V. J.; Jong, L.; Hobbs, P.; Chao, W. R.; Shroot, B.; Reichert, U. Identification of a unique binding protein specific for a novel retinoid inducing cellular apoptosis. Int. J. Cancer 2000, 86, 474-479.
43. Shipanova, I. N.; Glomb, M. A.; Nagaraj, R. H. Protein modification by methylglyoxal: Chemical nature and synthetic mechanism of a major fluorescent adduct. Arch. Biochem. Biophys. 1997, 344, 29-36.
44. Richardson, R. M.; Pares, X.; Cuchillo, C. M. Chemical modification by pyridoxal 5′-phosphate and cyclohexane-1,2-dione indicates that Lys-7 and Arg-10 are involved in the p2 phosphate-binding subsite of bovine pancreatic ribonuclease A. Biochem. J. 1990, 267, 593-599.
45. Jiang, Z. Y.; Thorpe, C. Modification of an arginine residue in pig kidney general acyl-coenzyme A dehydrogenase by cyclohexane-1,2-dione. Biochem. J. 1982, 207, 415-419.
46. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
47. Ek, F.; Manner, S.; Wistrand, L. G.; Frejd, T. Synthesis of fused tetrazole derivatives via a tandem cycloaddition and N-allylation reaction and parallel synthesis of fused tetrazole amines. J. Org. Chem. 2004, 69, 1346-1352.
48. Mancuso, A. J.; Huang, S.-L.; Swern, D. Oxidation of long-chain and related alcohols to carbonyls by dimethyl sulfoxide "activated" by oxalyl chloride. J. Org. Chem. 1978, 43, 2480-2482.
49. Cho, B. R.; Chajara, K.; Oh, H. J.; Son, K. H.; Jeon, S. J. Synthesis and nonlinear optical properties of 1,3,5-methoxy-2,4,6-tris(styryl)-benzene derivatives. Org. Lett. 2002, 4, 1703-1706.
50. Bouchain, G.; Leit, S.; Frechette, S.; Khalil, E. A.; Lavoie, R.; Moradei, O.; Woo, S. H.; Fournel, M.; Yan, P. T.; Kalita, A.; Trachy-Bourget, M. C.; Beaulieu, C.; Li, Z.; Robert, M. F.; MacLeod, A. R.; Besterman, J. M.; Delorme, D. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. J. Med. Chem. 2003, 46, 820-830.
51. Doyle, M. P.; Siegfried, B.; Dellaria, J. F., Jr. Alkyl nitrile-metal halide deamination reactions. 2. Substitutive deamination of aryl-amines by alkyl nitrites and copper(II) halides. A direct and remarkably efficient conversion of arylamines to aryl halides. J. Org. Chem. 1977, 42, 2426-2430.
52. Musso, D. L.; Clarke, M. J.; Kelley, J. L.; Boswell, G. E.; Chen, G. Novel 3-phenylprop-2-ynylamines as inhibitors of mammalian squalene epoxidase. Org. Biomol. Chem. 2003, 1, 498-506.
53. Brown, H. C.; Subrahmanyam, C.; Hamaoka, T.; Ravindran, N. Vinylic organoboranes. 13. A convenient stereospecific synthesis of (Z)-1-halo-1-alkenes from 1-alkynes via (E)-1-alkenylborane derivatives with halogens. J. Org. Chem. 1989, 54, 6068-6075.
54. Simoni, D.; Rossi, M.; Rondanin, R.; Mazzali, A.; Baruchello, R.; Malagutti, C.; Roberti, M.; Invidiata, F. P. Strong bicyclic guanidine base-promoted Wittig and Horner-Wadsworth-Emmons reactions. Org. Lett. 2000, 2, 3765-3768.
55. 1. J. Org. Chem. 1972, 37, 1810-1818.
56. Zabell, A. P.; Corden, S.; Helquist, P.; Stauffacher, C. V.; Wiest, O. Inhibition studies with rationally designed inhibitors of the human low molecular weight protein tyrosine phosphatase. Bioorg. Med. Chem. 2004, 12, 1867-1880.
57. Palacios, F.; Aparicio, D.; Vicario, J. Synthesis of quinolinylphosphane oxides and -phosphonates from N-arylimines derived from the phosphane oxides and phosphonates. Eur. J. Org. Chem. 2002, 4131-4136.
58. Klicic, J.; Friesner, F.; Liu, S.-Y.; Guida, W. Accurate prediction of acidity constants in aqueous solution via density functional theory and self-consistent reaction field methods. J. Phys. Chem. A 2002, 106, 1327-1335.
59. Li, H.; Kolluri, S. K.; Gu, J.; Dawson, M. I.; Cao, X.; Hobbs, P. D.; Lin, B.; Chen, G.; Lu, J.; Lin, F.; Xie, Z.; Fontana, J. A.; Reed, J. C.; Zhang, X. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000, 289, 1159-1164.
60. Zhang, Y.; Huang, Y.; Rishi, A. K.; Sheikh, M. S.; Shroot, B.; Rejchert, U.; Dawson, M.; Poirer, G.; Fontana, J. A. Activation of the p38 and JNK/SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid. Exp. Cell. Res. 1999, 247, 233-240.
61. Pfahl, M.; Piedrafita, F. J. Retinoid targets for apoptosis induction. Oncogene 2003, 22, 9058-9062.
62. Schubbert, S.; Lieuw, K.; Rowe, S. L.; Lee, C. M.; Li, X.; Loh, M. L.; Clapp, D. W.; Shannon, K. M. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 2005, 106, 311-317.
63. Yu, W. M.; Daino, H.; Chen, J.; Bunting, K. D.; Qu, C. K. Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling. J. Biol. Chem. 2006, 281, 5426-5434.
64. Zhu, X. Z.; Yu, Y. Z.; Fang, Y. M.; Liang, Y.; Lu, Q. H.; Xu, R. Z. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]. Zhonghua Yi Xue Za Zhi 2005, 85, 1903-1906.
65. Tauchi, T.; Miyazawa, K.; Feng, G. S.; Broxmeyer, H. E.; Toyama, K. A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules. J. Biol. Chem. 1997, 272, 1389-1394.
66. Farhana, L.; Dawson, M. I.; Huang, Y.; Zhang, Y.; Rishi, A. K.; Reddy, K. B.; Freeman, R. S.; Fontana, J. A. Apoptosis signaling by the novel compound 3-Cl-AHPC involves increased EGFR proteolysis and accompanying decreased phosphatidylinositol 3-kinase and AKT kinase activities. Oncogene 2004, 23, 1874-1884.
67. Tchilian, E. Z.; Beverley, P. C. Altered CD45 expression and disease. Trends Immunol. 2006, 27, 146-153.
68. Miyachi, H.; Tanaka, Y.; Gondo, K.; Kawada, T.; Kato, S.; Sasao, T.; Hotta, T.; Oshima, S.; Ando, Y. Altered expression of CD45 isoforms in differentiation of acute myeloid leukemia. Am. J. Hematol. 1999, 62, 159-164.
69. Arsenou, E. S.; Papadimitriou, E. P.; Kliafa, E.; Hountala, M.; Nikolaropoulos, S. S. Effects of retinoic acid steroidal analogs on human leukemic HL60 cell proliferation in vitro and on angiogenesis in vivo. Anticancer Drugs 2005, 16, 151-158.
70. Dawson, M. I.; Zhang, X.-K. Discovery and design of retinoic acid receptor and retinoid X receptor class-and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid. Curr. Med. Chem. 2002, 9, 623-637.
71. Peterson, V. J.; Barofsky, E.; Deinzer, M. L.; Dawson, M. I.; Feng, K. C.; Zhang, X.-K.; Madduru, M. R.; Leid, M. Mass-spectrometric analysis of agonist-induced retinoic acid receptor γ conformational change. Biochem. J. 2002, 362, 173-181.
72. Rao, A. V. R.; Chakraborty, T. K.; Reddy, K. L.; Rao, A. S. An expeditious approach for the synthesis of β-hydroxylaryl α-amino acids present in vancomycin. Tetrahedron Lett. 1994, 35, 5043-5046.
73. Wittenberger, S. J.; Donner, B. G. Dialkyltin oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazoles. J. Org. Chem. 1993, 58, 4139-4141.
74. A receptors initiating sedation. Eur. J. Pharmacol. 2000, 401, 271-287.
75. A receptors initiating the anxiolytic response. Bioorg. Med. Chem. 2000, 8, 2527-2538.
76. Stewart, J. J. P. A semiempirical molecular orbital program. MOPAC. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
77. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; AlLaham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, Revision C.02, Gaussian, Inc., Wallingford, CT, 2004.
78. Nangia-Makker, P.; Honjo, Y.; Sarvis, R.; Akahani, S.; Hogan, V.; Pienta, K. J.; Raz, A. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 2000, 156, 899-909.